Project/Area Number |
25461672
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Dermatology
|
Research Institution | Nagasaki University |
Principal Investigator |
OGAWA Fumihide 長崎大学, 医歯薬学総合研究科(医学系), 客員研究員 (10333519)
|
Co-Investigator(Kenkyū-buntansha) |
KUWATSUKA Yutaka 長崎大学, 医歯薬学総合研究科(医学系), 助教 (90437864)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2015: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 細胞外マトリックス / 全身性強皮症 / マウスモデル / vorinostat / HDAC阻害薬 |
Outline of Final Research Achievements |
Systemic sclerosis (SSc) is connective tissue disorder characterized by severe fibrosis of the skin and various internal organs. Tight skin (TSK/+) mouse is a putative murine model of SSc characterized by excessive collagen deposition in skin. Vorinostat, a kind of histone deacetylase inhibitor, was injected subcutaneously into the back of the TSK/+ and wild type mice. As a result, vorinostat could not decrease the development of TSK mouse skin fibrosis. We examined the suitable concentration of the vorinostat in vitro by using human skin fibroblasts of SSc or normal human skin. However, mRNA expressions of type I collagen or fibrogenic cytokines were not markedly attenuated by vorinostat administration. These results suggest that vorinostat have little specificity on the SSc skin fibrosis. Also, these result may reflect the fact that vorinostat may have little effect on the HDAC inhibiton relative to other HDAC inhibitors.
|